Piper Sandler Remains a Buy on Harmony Biosciences Holdings (HRMY)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) today and set a price target of $44.00. The company’s shares closed yesterday at $31.26.

Amsellem covers the Healthcare sector, focusing on stocks such as Alkermes, Supernus Pharmaceuticals, and Corcept Therapeutics. According to TipRanks, Amsellem has an average return of -3.0% and a 41.37% success rate on recommended stocks.

In addition to Piper Sandler, Harmony Biosciences Holdings also received a Buy from Needham’s Ami Fadia in a report issued yesterday. However, on the same day, Goldman Sachs reiterated a Sell rating on Harmony Biosciences Holdings (NASDAQ: HRMY).

Based on Harmony Biosciences Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $168.41 million and a net profit of $26.61 million. In comparison, last year the company earned a revenue of $128.31 million and had a net profit of $48.51 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Harmony Biosciences Holdings (HRMY) Company Description:

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.